AI-Discovered Drugs Are Running 80-90% Phase I Success Rates

An industry-wide analysis finds AI-first drug candidates are achieving Phase I success rates roughly double the historical 50% average. With fewer than 15 AI-first candidates completing Phase II and none yet FDA-approved, 2026 becomes the year the hype meets definitive clinical validation.